{
    "ticker": "CYTH",
    "name": "Cyclo Therapeutics, Inc.",
    "description": "Cyclo Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing innovative therapies for neurodegenerative diseases. Founded in 2014, Cyclo's lead product candidate, Trappsol\u00ae Cyclo\u2122, is designed to treat Niemann-Pick Disease Type C (NPC), a rare and devastating genetic disorder that affects lipid metabolism in the brain. The company's mission is to transform the treatment of NPC and other neurodegenerative disorders through its proprietary cyclodextrin-based technology, which enhances the delivery of therapeutic agents across the blood-brain barrier. Cyclo Therapeutics is committed to improving the lives of patients and their families by advancing its clinical programs and collaborating with leading research institutions. The company is actively engaged in ongoing clinical trials and is exploring additional indications for its technology. With a strong focus on innovation, Cyclo Therapeutics aims to establish itself as a leader in the field of rare disease treatment, leveraging its expertise in drug development and patient advocacy.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "Gainesville, Florida, USA",
    "founded": "2014",
    "website": "https://www.cyclotherapeutics.com",
    "ceo": "N. Scott Fine",
    "social_media": {
        "twitter": "https://twitter.com/CycloTherapeutics",
        "linkedin": "https://www.linkedin.com/company/cyclo-therapeutics-inc"
    },
    "investor_relations": "https://www.cyclotherapeutics.com/investors",
    "key_executives": [
        {
            "name": "N. Scott Fine",
            "position": "CEO"
        },
        {
            "name": "David P. Dyer",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Therapeutics",
            "products": [
                "Trappsol\u00ae Cyclo\u2122"
            ]
        }
    ],
    "seo": {
        "meta_title": "Cyclo Therapeutics, Inc. | Innovating Treatments for Neurodegenerative Diseases",
        "meta_description": "Cyclo Therapeutics, Inc. is dedicated to developing innovative therapies for neurodegenerative diseases like Niemann-Pick Disease Type C. Learn more about our mission and products.",
        "keywords": [
            "Cyclo Therapeutics",
            "Niemann-Pick Disease",
            "Trappsol Cyclo",
            "Neurodegenerative Diseases",
            "Biotechnology"
        ]
    },
    "faq": [
        {
            "question": "What does Cyclo Therapeutics specialize in?",
            "answer": "Cyclo Therapeutics specializes in developing therapies for neurodegenerative diseases, particularly Niemann-Pick Disease Type C."
        },
        {
            "question": "Where is Cyclo Therapeutics headquartered?",
            "answer": "Cyclo Therapeutics is headquartered in Gainesville, Florida, USA."
        },
        {
            "question": "What is Trappsol\u00ae Cyclo\u2122?",
            "answer": "Trappsol\u00ae Cyclo\u2122 is Cyclo Therapeutics' lead product candidate aimed at treating Niemann-Pick Disease Type C."
        },
        {
            "question": "When was Cyclo Therapeutics founded?",
            "answer": "Cyclo Therapeutics was founded in 2014."
        }
    ],
    "competitors": [
        "AVXL",
        "RGEN",
        "SAVA"
    ],
    "related_stocks": [
        "AMGN",
        "GILD",
        "VRTX",
        "REGN"
    ]
}